BIOPROCESS OUTSOURCING FEATURED ARTICLES

DARPA’s Challenge: Manufacture A Biopharmaceutical In Less Than 24 Hours
DARPA’s Challenge: Manufacture A Biopharmaceutical In Less Than 24 Hours

In order to ensure American soldiers fighting in remote locations overseas can receive the biopharmaceuticals they need on time, Defense Advanced Research Projects Agency (DARPA) created a program called Biologically-derived Medicines on Demand (Bio-MOD). The goal of Bio-MOD is to build a system that has the ability to create an on-demand biopharmaceutical in less than 24 hours. I spoke with one of the teams working on this effort about how they intend to accomplish this and what it could mean to the future of the industry.

  • Should Your Clinical Outsourcing Model Be Functional, Full-Service, Or A Hybrid FSP?
    Should Your Clinical Outsourcing Model Be Functional, Full-Service, Or A Hybrid FSP?

    Clinical outsourcing is constantly changing as a drug companies seek new ways of working faster, leaner, and to higher standards. This is causing sponsors to reexamine different outsourcing models and challenge traditional approaches such as, traditional outsourcing, full-service models, or Functional Outsourcing (FSP) models.

  • Innovation In Expression Systems Yields Increase Productivity
    Innovation In Expression Systems Yields Increase Productivity

    Technological advances in genetic engineering particularly expression systems (the genetically modified cells that express desired proteins), process design, and equipment continue to be combined such that the same amount of drug product can be manufactured at a much smaller scale. According to the Biopharmaceutical Manufacturing Capacity and Production Survey revealed an overall increase in productivity and efficiency in biomanufacturing.

  • Israel Drives Middle East Biotech Start-ups
    Israel Drives Middle East Biotech Start-ups

    Israel has been called, accurately, a nation of start-ups. With its scientifically oriented population and entrepreneurial drive, the nation is driving Middle East biotech. Approximately 60 percent of Israel’s life sciences companies focus on medical devices, while about 35 percent focus on biopharmaceuticals. Typically, 40 to 60 biotech companies are founded each year.

More Featured Articles

BIOPROCESS OUTSOURCING WHITE PAPERS & CASE STUDIES

  • Streamline Pharma Drug Development: Yes, It's Time.
    Streamline Pharma Drug Development: Yes, It's Time.

    While the largest pharmaceutical companies have done well over the years, many now trail their smaller brethren. What’s going on? 

  • The Timely Rise Of The CDMO
    The Timely Rise Of The CDMO

    The complexity of today’s molecules and the growing majority of new molecule development are calling for a new method of drug production. Biopharma companies of all sizes are looking to vendors to manage development, manufacturing, and capacity needs. The question is: Are they keeping up?

  • The Client Experience—Key to a CDMO’s Success
    The Client Experience—Key to a CDMO’s Success

    In the dynamic contract development and manufacturing organization (CDMO) industry, client-focused businesses succeed in retaining and growing our client base by delivering on project objectives and satisfying a client’s expectations.

More White Papers & Case Studies

BIOPROCESS OUTSOURCING PRODUCTS & SERVICES

Small Molecule Development And Manufacturing Services Small Molecule Development And Manufacturing Services

High-quality API via the development of a scalable process that will meet demand at each stage of your product’s life cycle. Complete drug product services from preformulation screening through clinical development to commercial supply. A comprehensive range of oral solid, sterile and softgel dosage forms with expertise in high-potency products. Unique solutions to overcome the toughest solubility challenges and accelerate your path to proof of concept.

Biologics Contract Development Biologics Contract Development

Comprehensive contract development. Reliable cGMP manufacturing. Gain a competitive advantage in both by choosing Patheon for your biopharmaceuticals and biosimilars. You’ll have access to end-to-end, fully integrated services for both drug substances and drug products, delivered on time and on budget. A simplified supply chain that accelerates development and keeps you ahead in the rapidly changing world of biologics.

Drug Product Development Services Drug Product Development Services

Considering that 90% of drug candidates have bioavailability issues, making sure your program is prepared for all phases of clinical trials from the very start is the fast way forward. Patheon Solubility Enhancement Services approaches BCS II and IV drug substance solubility issues a fundamentally different way that identifies the solubility enhancement technologies most likely to work before you get started. That helps eliminate rework and worry later on.

More Products & Services